HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
Clinical trial NCT04676477 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04676477
- Sponsor
- Daiichi Sankyo
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-11
- Primary completion
- 2025-01-31
- Enrollment
- 246
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.